Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder
Year: 2021
Type: review
Abstract: Allergic and immunologic skin diseases negatively impact the quality of life (QoL) of affected patients with detrimental consequences. Nonetheless, in everyday clinical practice the evaluation of QoL is often overlooked. Considering the increasing prevalence of atopic dermatitis, allergic contact dermatitis, hereditary angioedema, cutaneous mastocytosis, and urticaria, it is essential to determine the effects of allergic and immunologic skin diseases on QoL. A joint meeting (GET TOGETHER 2021) of the Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC) and the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) aimed to summarize the features of the main QoL tools used in these diseases and to describe the extent of QoL impairment as well as the impact of treatments on QoL, particularly biologic therapies. The assessment of QoL in patients with allergic and immunologic skin diseases relies on generic, organ-specific and disease-specific questionnaires. While generic and organ-specific questionnaires allow comparison between different diseases, disease-specific questionnaires are designed and validated for specific cohorts: the QoL Index for Atopic Dermatitis (QoLIAD) and the Childhood Atopic Dermatitis Impact Scale (CADIS) in atopic dermatitis, the ACD-11 in allergic contact dermatitis, the Angioedema QoL Questionnaire (AE-QoL) and the Hereditary Angioedema QoL questionnaire (HAE-QoL) in hereditary angioedema, the Mastocytosis QoL Questionnaires (MCQoL e MQLQ) in cutaneous mastocytosis, and the Chronic Urticaria QoL questionnaire (CU-Q2oL) in urticaria. Among the many factors that variably contribute to QoL impairment, pruritus can represent the leading cause of patient discomfort. Biologic therapies significantly ameliorate QoL in atopic dermatitis, hereditary angioedema, mastocytosis and chronic urticaria. In general, adequate management strategies are essential for improving QoL in patients with allergic and immunologic skin diseases.
Source: Clinical and Molecular Allergy
Authors: Ester Di Agosta, Lorenzo Salvati, Monica Corazza, Ilaria Baiardini, Francesca Ambrogio, Luisa Angileri, Elettra Antonelli, Federica Belluzzo, Domenico Bonamonte, Laura Bonzano, Raffaele Brancaccio, Paolo Custurone, Aurora De Marco, Aikaterini Detoraki, Adriana Di Guida, Elisabetta Di Leo, Marta Fantò, Filippo Fassio, Silvia Mariel Ferrucci, Caterina Foti, Rosella Gallo, Alessia Gatta, Fabrizio Guarneri, Lucia Guidolin, Katharina Hansel, Donatella Lamacchia, Carla Lombardo, Paola Lucia Minciullo, Maddalena Napolitano, Alessandro Pannofino, Andrea Paravisi, Roberta Parente, Maria Passante, Cataldo Patruno, Diego Peroni, Cristina Quecchia, Natale Schettini, Giuseppe Spadaro, Luca Stingeni, Daniele Tarrini, Marta Tramontana, Eustachio Nettis, Oliviero Rossi
Institutions: University of Florence, University of Ferrara, Ospedale Policlinico San Martino, IRCCS Humanitas Research Hospital, University of Genoa, University of Bari Aldo Moro, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Perugia, Azienda Sanitaria Unità Locale di Reggio Emilia, Azienda Sanitaria Locale Salerno, University of Messina, Federico II University Hospital, University of Naples Federico II, Ospedale Generale Regionale Francesco Miulli, Policlinico Umberto I, Sapienza University of Rome, Nuovo Ospedale San Giovanni di Dio, University of Chieti-Pescara, University of Verona, Azienda Ospedaliera Universitaria Policlinico "G. Martino", University of Molise, University of Salerno, Magna Graecia University, University of Pisa, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Turin, Azienda Ospedaliero-Universitaria Careggi
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,190
OpenAlex ID: W4200317402